<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">27898692</PMID>
        <DateCompleted>
            <Year>2017</Year>
            <Month>06</Month>
            <Day>30</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2018</Year>
            <Month>12</Month>
            <Day>02</Day>
        </DateRevised>
        <Article PubModel="Electronic-eCollection">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2016</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Targeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma Cells.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e0166233</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0166233</ELocationID>
            <Abstract>
                <AbstractText>Cyclin-dependent kinase 2 (CDK2) has been reported to be essential for cell proliferation in several human tumours and it has been suggested as an appropriate target to be considered in order to enhance the efficacy of treatment regimens based on the use of DNA damaging drugs. We evaluated the clinical impact of CDK2 overexpression on a series of 21 high-grade osteosarcoma (OS) samples profiled by using cDNA microarrays. We also assessed the in vitro efficacy of the CDKs inhibitor roscovitine in a panel of drug-sensitive and drug-resistant human OS cell lines. OS tumour samples showed an inherent overexpression of CDK2, and high expression levels at diagnosis of this kinase appeared to negatively impact on clinical outcome. CDK2 expression also proved to be relevant for in vitro OS cells growth. These findings indicated CDK2 as a promising candidate therapeutic marker for OS and therefore we assessed the efficacy of the CDKs-inhibitor roscovitine in both drug-sensitive and -resistant OS cell lines. All cell lines resulted to be responsive to roscovitine, which was also able to increase the activity of cisplatin and doxorubicin, the two most active DNA damaging drugs used in OS chemotherapy. Our results indicated that combined treatment with conventional OS chemotherapeutic drugs and roscovitine may represent a new candidate intervention approach, which may be considered to enhance tumour cell sensitivity to DNA damaging drugs.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Vella</LastName>
                    <ForeName>Serena</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tavanti</LastName>
                    <ForeName>Elisa</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hattinger</LastName>
                    <ForeName>Claudia Maria</ForeName>
                    <Initials>CM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fanelli</LastName>
                    <ForeName>Maril√π</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Versteeg</LastName>
                    <ForeName>Rogier</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, Academic Medical Center, University of Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koster</LastName>
                    <ForeName>Jan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncogenomics, Academic Medical Center, University of Amsterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picci</LastName>
                    <ForeName>Piero</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serra</LastName>
                    <ForeName>Massimo</ForeName>
                    <Initials>M</Initials>
                    <Identifier Source="ORCID">http://orcid.org/0000-0003-0742-1177</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Italy.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>29</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011687">Purines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0ES1C2KQ94</RegistryNumber>
                <NameOfSubstance UI="D000077546">Roscovitine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>80168379AG</RegistryNumber>
                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.22</RegistryNumber>
                <NameOfSubstance UI="D051357">Cyclin-Dependent Kinase 2</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051357" MajorTopicYN="N">Cyclin-Dependent Kinase 2</DescriptorName>
                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
                <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004249" MajorTopicYN="Y">DNA Damage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004357" MajorTopicYN="N">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D020868" MajorTopicYN="N">Gene Silencing</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012516" MajorTopicYN="N">Osteosarcoma</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000077546" MajorTopicYN="N">Roscovitine</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2016</Year>
                <Month>06</Month>
                <Day>29</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2016</Year>
                <Month>10</Month>
                <Day>25</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>11</Month>
                <Day>30</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2017</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27898692</ArticleId>
            <ArticleId IdType="doi">10.1371/journal.pone.0166233</ArticleId>
            <ArticleId IdType="pii">PONE-D-16-26025</ArticleId>
            <ArticleId IdType="pmc">PMC5127503</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>Expert Opin Ther Targets. 2010 Nov;14(11):1199-212</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20932174</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nature. 2004 Nov 18;432(7015):316-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15549093</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Pharmacol Ther. 2014 May;142(2):258-69</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24362082</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 Aug 15;68(16):6661-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18701490</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2011 Jun;10 (6):1018-27</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21490307</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cell Cycle. 2003 Jan-Feb;2(1):53-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12695689</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Res. 2007 Feb;5(2):145-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17314272</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Emerg Drugs. 2010 Dec;15(4):615-34</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20690888</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Anticancer Res. 1993 Mar-Apr;13(2):323-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8100126</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Emerg Drugs. 2015 Sep;20(3):495-514</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26021401</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nucleic Acids Res. 2012 Jan;40(2):477-86</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21937510</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Curr Opin Cell Biol. 2013 Dec;25(6):772-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24011867</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Drug Discov Today. 2008 Oct;13(19-20):875-81</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18639646</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Investig Drugs. 2003 Jun;12(6):955-70</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12783600</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Manag Res. 2014 Feb 19;6:77-92</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24600246</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Development. 2013 Aug;140(15):3079-93</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23861057</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2003 Sep 29;22(42):6609-20</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14528286</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biotechnol. 2015 May 20;202:40-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25747275</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2008 Oct 1;68(19):7966-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18829554</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Cancer. 2010 Dec;46(18):3243-50</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20822897</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Mol Cell Biol. 2004 Oct;5(10 ):792-804</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15459660</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Chromosomes Cancer. 2012 Jan;51(1):10-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22034077</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Int J Cancer. 1999 Feb 9;80(4):581-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9935160</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Br J Cancer. 2013 Nov 12;109(10):2607-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24129234</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>World J Gastroenterol. 2008 Sep 7;14 (33):5162-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18777593</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Environ Mol Mutagen. 2000;35(3):206-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">10737956</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Genes Chromosomes Cancer. 2010 Jan;49(1):40-51</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19787792</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14508085</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Oncogene. 2005 Apr 18;24(17):2909-15</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15838524</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann N Y Acad Sci. 2009 Aug;1171:228-41</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19723060</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>PLoS One. 2012;7(12):e52356</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">23285007</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Histopathology. 2015 Sep;67(3):338-47</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25600168</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Orthop Relat Res. 2008 Sep;466(9):2168-75</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18607665</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2005 Sep 1;65(17 ):7717-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16140939</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Drug Discov. 2009 Jul;8(7):547-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19568282</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Eur J Biochem. 1997 Jan 15;243(1-2):527-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">9030781</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2005 Jul 1;11(13):4875-87</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16000586</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Science. 1993 Dec 24;262(5142):2050-4</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">8266103</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2012 Oct;11(10):2265-73</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22821149</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Oncol. 2004 Jan;15(1):151-60</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">14679136</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>DNA Repair (Amst). 2009 Jan 1;8(1):6-18</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18832049</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Gynecol Oncol. 2007 May;105(2):462-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17300833</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Expert Opin Pharmacother. 2015;16(18):2727-36</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26512909</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest New Drugs. 2014 Dec;32(6):1167-80</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">25193492</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Rev Cancer. 2009 Mar;9(3):153-66</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19238148</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Blood. 2005 Jun 1;105(11):4484-91</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15692065</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Ann Transl Med. 2015 Jun;3(10):135</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">26207228</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cytotechnology. 2014 Aug;66(4):567-74</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">24801578</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Nat Protoc. 2006;1(1):23-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17406208</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>